Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Quarterly on Schedule

<< Previous

Bullboard Posts

Next >>

Comment by RickyBobbyTOon Aug 12, 2022 9:33am

122 Views

Post# 34891005

RE:RE:Quarterly on Schedule

Godspeed* (autocorrect)

RickyBobbyTO wrote:

this was way more honest than last years blindsided financing. Everyone knows they need cash, let the chips fall as they may. Good speed and good luck. We are almost mid august so bankers are returning to their desks, let it be quick and painless.

pm1861 wrote: Hello all,

After reading the latest NR I am left feeling a bit disappointed. While the release highlights the accomplishments ( and there are many), it did not provide any detail on the recent Arc deal. Good that they will seek approval for additional sites for TIGRIS. Further, there seems to be some foreshadowing to another raise from the
company

"While the Company continues to maintain a low cost operating structure for its base business operations, it anticipates its operating costs to increase throughout 2022 as Spectral’s Tigris trial enrolment is expected to increase, combined with incremental costs associated with Dialco’s upcoming usability trial for DIMI and the increase in field resources for the marketing and commercialization activities of its RRT devices."

Hopefully it won't come to more dilution. My conviction in this company is still strong. Just wanted a little bit more.

PM